Výsledky vyhledávání - "Hans M. Princen"

Akademický článek

Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion[S]

Autor: Kanami Sugimoto-Kawabata, Hiroshi Shimada, Kaoru Sakai, Kazuo Suzuki, Thomas Kelder, Elsbet J. Pieterman, Louis H. Cohen, Louis M. Havekes, Hans M. Princen, Anita M. van den Hoek

Publikováno v: Journal of Lipid Research, Vol 54, Iss 5, Pp 1255-1264 (2013)

Bile acid sequestrants (BASs) are cholesterol-lowering drugs that also affect hyperglycemia. The mechanism by which BASs exert these and other metabolic effects beyond cholesterol lowering remains poorly understood. The present study aimed to investi

Externí odkaz: https://doaj.org/article/aef6254d56e24440b004893f7a2d5f51

Zobrazit plný text záznamu

Abstract 246: Anacetrapib Adds to the Antiatherogenic Effect of Atorvastatin, Mainly by Increasing the Clearance of Non-HDL Cholesterol

Autor: Sam J van der Tuin, Susan Kuhnast, José W Van der Hoorn, Jan B van Klinken, Branko Simic, Elsbet J Pieterman, Louis M Havekes, Ulf Landmesser, Thomas F Luscher, Ko Willems-van Dijk, Patrick C Rensen, J W Jukema, Hans M Princen

Publikováno v: Arteriosclerosis, Thrombosis, and Vascular Biology. 34

Introduction: The residual risk that remains after statin treatment has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers choleste

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4d745351103b05c2c030450a60effcc
https://doi.org/10.1161/atvb.34.suppl_1.246

Zobrazit plný text záznamu

Abstract 69: Anacetrapib Dose-dependently Decreases Atherosclerosis Development and Adds to the Beneficial Effects of Atorvastatin in APOE*3Leiden.CETP Mice

Autor: Susan Kühnast, Sam J van der Tuin, Louis M Havekes, Ko Willems van Dijk, Patrick C Rensen, José W van der Hoorn, J W Jukema, Hans M Princen

Publikováno v: Arteriosclerosis, Thrombosis, and Vascular Biology. 33

Introduction The residual risk of cardiovascular disease that remains after statin treatment has triggered the search for a secondary treatment target. Epidemiological studies propose HDL-cholesterol (HDL-C) as a possible candidate. Cholesteryl ester

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::16e6590eeb3fe961b0624a002057da17
https://doi.org/10.1161/atvb.33.suppl_1.a69

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání